Mingchuan Guo
Longgang Central Hospital(CN)Modulation Therapeutics (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Alzheimer's disease research and treatments, Lung Cancer Treatments and Mutations, Angiogenesis and VEGF in Cancer, Ovarian cancer diagnosis and treatment
Most-Cited Works
- → Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy(2014)151 cited
- Synergistic protective effect of picroside II and NGF on PC12 cells against oxidative stress induced by H2O2.(2008)
- → Kushenflavonoids induce apoptosis in tumor cells by inhibition of NF‐κB activation and multiple receptor tyrosine kinase activities(2006)38 cited
- → The Neuroprotective Effect of Picroside II from Hu-Huang-Lian against Oxidative Stress(2007)38 cited
- → Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta‐Analysis(2022)10 cited
- → Abstract 4499: HM5016699, a novel and selective PI3K/mTOR dual inhibitor(2011)
- → Abstract 1051: Combination of senaparib with temozolomide for the treatment of cancer(2022)
- → Abstract 1808: HM-032, a novel PI3K/mTOR dual inhibitor, is active on K-Ras/Raf mutation tumors through up-regulation of Bim(2012)